Specific Deubiquitinating Enzymes Promote Host Restriction Factors Against HIV/SIV Viruses

Wenying Gao†, Yajuan Rui‡, Guangquan Li‡, Chenyang Zhai†, Jiaming Su‡, Han Liu‡, Wenwen Zheng‡, Baisong Zheng†, Wenyuan Zhang†, Yongjun Yang§, Shucheng Hua* and Xiaofang Yu†,2*

† Center for Pathogen Biology and Infectious Diseases, Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China, ‡ Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, Ministry of Education), Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, § Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, China, ‡ Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, China, * Key Laboratory of Zoonosis, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, China

Hijacking host ubiquitin pathways is essential for the replication of diverse viruses. However, the role of deubiquitinating enzymes (DUBs) in the interplay between viruses and the host is poorly characterized. Here, we demonstrate that specific DUBs are potent inhibitors of viral proteins from HIVs/simian immunodeficiency viruses (SIVs) that are involved in viral evasion of host restriction factors and viral replication. In particular, we discovered that T cell-functioning ubiquitin-specific protease 8 (USP8) is a potent and specific inhibitor of HIV-1 virion infectivity factor (Vif)-mediated apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3)G (A3G) degradation. Ectopic expression of USP8 inhibited Vif-induced A3G degradation and suppressed wild-type HIV-1 infectivity even in the presence of Vif. In addition, specific DUBs repressed Vpr-, Vpu-, and Vpx-triggered host restriction factor degradation. Our study has revealed a previously unrecognized interplay between the host’s DUBs and viral replication. Enhancing the antiviral activity of DUBs therefore represents an attractive strategy against HIVs/SIVs.

Keywords: USP8, deubiquitinating enzymes, antiviral activity, viral proteins, ubiquitin ligase

INTRODUCTION

Ubiquitin modification of proteins regulates their functions and is involved in virtually all aspects of cellular processes (1). Ubiquitin modification is further regulated by deubiquitinating enzymes (DUBs). DUBs have been divided according to active site homology into six broad classes (2): Ub-specific proteases (USPs), Ub C-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs), Machado–Joseph disease protein domain proteases, JAMM/MPN domain-associated metalloproteases (JAMMs), and monocyte chemotactic protein-induced proteins (MCPIPs) (3). Within the six classes of DUBs, USPs are highly diversified, consisting of more than 50 members. Many studies have reported mutations in USPs involved in multiple biological processes (4). However, the role of DUBs in the interplay between viruses and the host is poorly characterized.
Ubiquitin modification of proteins regulates their function (1, 4, 5) and the reverse process, deubiquitination, is also important for many biological events (6). The importance of deubiquitinating enzyme function is underscored by its frequent deregulation in human diseases such as cancer, infections, and neurological disease, making these enzymes potential drug targets. Also, hijacking host ubiquitin pathways is essential for the replication of diverse viruses (7, 8). The host’s cytidine deaminase apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) proteins are potent inhibitors of virion infectivity factor (Vif)-deficient human immunodeficiency virus 1 (HIV-1ΔVif) (9, 10). APOBEC3B/DE/G/F (A3B/DE/G/F) proteins become packaged into HIV-1 virions during virus production and inhibit viral reverse transcription in newly infected target cells. Other APOBEC3 protein family members, including APOBEC3A (A3A), APOBEC3C (A3C), and APOBEC3H (A3H), also impair HIV-1 replication by packaging into virions (11). The Vif protein of HIV-1 neutralizes APOBEC3’s antiviral functions by forming a viral-specific CRL5 E3 ubiquitin ligase complex consisting of CUL5, ElOB/C, and CBF β-TrCP to form a RING finger domain for ubiquitination and degradation (12–14) to promote the polyubiquitination and degradation of APOBEC3 substrates (15).

Three other HIV/simian immunodeficiency virus (SIV) accessory proteins, Vpu, Vpr, and Vpx, are also essential components of viral replication and pathogenesis. Ubiquitin modification is vital for them on the process of target protein destruction. HIV-1 Vpu hijacks CUL1 and β-TrCP to form a CRL1 E3 ubiquitin ligase complex, triggering the degradation of BST-2 (16) and PSGL-1 (17). Vpr recruits DCAF1, DDB1, and CUL4 to form the CRL4 E3 ubiquitin ligase complex to induce the degradation of HLTF (18). Vpx proteins of HIV-2Rod and certain SIVs overcome the antiviral function of SAMHD1 in myeloid cells by inducing its polyubiquitination and degradation (19, 20).

In this report, we demonstrate that DUBs are potent inhibitors of viral evasion of host restriction. We have identified various DUBs inhibiting functions of HIV Vif, Vpr, Vpu, and Vpx proteins. Collectively, our study reveals a previously unrecognized interplay between the host’s DUBs and viral replication. Enhancing the antiviral activity of DUBs therefore represents an attractive strategy against HIVs/SIVs.

RESULTS

T Cell-Specific USP8 Inhibits Vif-Induced A3G Degradation and Suppresses Wild-Type HIV-1 Infectivity

The deubiquitination enzyme USP8 is a human T cell-specific factor regulating T-cell maturation and functions (21, 22), and CD4+ T cells are primary targets of HIV-1 infection. HIV-1 is potently inhibited by several human cytidine deaminases that are members of human APOBEC3 proteins. HIV-1 Vif neutralizes some APOBEC3’s antiviral functions by forming viral-specific CRL5 E3 ubiquitin ligase complexxes (12, 13, 23, 24) to promote the polyubiquitination and degradation of APOBEC3 substrates (Figure 1A). Whether any host factors involved in the deubiquitination pathway can influence Vif function has not been explored.

We observed that USP8 is highly expressed in primary CD4+ T cells and myeloid cells compared with HEK293T cells and RD cells (Figures 1B, C). Primary CD4+ T cells and myeloid cells are the preferred target cells of HIV-1. We screened a library of mammalian expression vectors that encode 32 USPs twice and discovered USP8 is distinguished from the group. USP8 significantly impaired Vif-triggered APOBEC3G (A3G) degradation (Supplementary Figures S1H, I). To investigate whether endogenous USP8 in T cells has an effect on Vif-induced A3G degradation, we generated USP8 knocking down stable cell line in H9 T cells (Supplementary Figure S1A). shCon and shUSP8 H9 cells were infected with wild-type (WT) HIV-1 at the same titer or mock infected. As shown in Figure 1D, silencing USP8 has no effect on endogenous A3G expression (lanes 1 and 3). A3G was degraded during HIV-1 infection (lanes 1 and 2). Surprisingly, A3G degradation was enhanced in virus-infected shUSP8 H9 cells (lanes 2 and 4). In addition, cell supernatants were collected at different time points, and virus infectivity was assessed using TZM-BL indicator cells. We found that USP8 knocking down had a positive effect on HIV-1 progeny virus replication (Figure 1E). A similar result was also determined in primary CD4+ cells (Supplementary Figure S1B). Since USP8 expression in HEK293T cells is lower than that in CD4+ T cells, we detected whether increasing the USP8 expression could affect HIV-1 Vif function in HEK293T cells. As a result, increasing the USP8 expression effectively inhibited HIV-1 Vif-induced A3G degradation (Figure 1F). In the absence of exogenous USP8 expression, HIV-1 Vif induced a >70% reduction in A3G (Figure 1F, lane 5) when compared to control cells (Figure 1F, lane 4). The Vif-induced degradation of A3G was essentially abolished in the presence of increasing amounts of USP8 (Figure 1F, lanes 6 and 7). In the absence of Vif, A3G expression was not affected by USP8 (Figure 1F, lanes 1–3). Consistent with previous reports, we also observed that USP8 could rescue Vif expression in a dose-dependent manner, since Vif was ubiquitinated and degraded via the proteasome pathway (25) (Figure 1F). Furthermore, silencing endogenous USP8 expression (Supplementary Figure S1C) enhanced HIV-1 Vif-mediated A3G degradation in HEK293T cells (Supplementary Figures S1C, D). The ability of HIV-1 Vif to counteract A3G is quite conserved among different HIV-1 subtypes. To investigate whether USP8 blocking of anti-A3G activity of Vif is universal, seven viral isolates from patients representing seven HIV-1 subtypes Vif molecules were selected (26, 27), except NL4-3 Vif. We validated that USP8 has the ability to block the anti-A3G activity of Vif molecules from diverse HIV-1 subtypes (Figure 1G).

To examine the possible effect of USP8 on HIV-1 infection, we first co-expressed increasing amounts of USP8 with HIV-1 (NL4-3). USP8 expression had no detectable effect on viral protein expression, as determined by the expression of intracellular HIV-1 Pr55Gag in HEK293T cells (Supplementary Figure S1E). Virus release (Supplementary Figure S1F) and the infectivity of the
released virus (Supplementary Figure S1G) were also unaffected by USP8 expression in the absence of A3G. In contrast, in the presence of USP8, intracellular A3G expression (Figure 1H) and virion incorporation of A3G (Figure 1I) were increased, even in the presence of HIV-1 Vif. At the same time, the infectivity of the released HIV-1 was reduced in the presence of USP8 (Figure 1J), which is consistent with the increased amount of A3G virion packaging. Combined with these data, these results indicate that
USP8 exerts its potent antiviral effect through Vif. USP8 antagonized the ability of HIV-1 Vif to suppress the antiviral function of A3G, resulting in an enhanced antiviral activity of A3G against Vif-containing HIV-1.

The Active Site of the USP8 Enzyme Is Required for Inhibition of HIV-1 Vif Function

In addition to A3G, A3H-Haplotype II (hap II), which is overcome by HxB2 Vif (26), and A3F are also potent inhibitors of HIV-1 that are neutralized by Vif (13, 28, 29). We observed that USP8 can efficiently inhibit HIV-1 Vif-induced degradation of A3F (Figures 2A, B) and A3H-HapII (Figures 2C, D). The degradation of other known HIV-1 Vif targets, such as A3C (Supplementary Figures S2A, B) and A3DE (Supplementary Figures S2C, D), was also inhibited by USP8. Non-primate lentiviral Vif from bovine immunodeficiency virus (BIV) targets cow APOBEC3 proteins (30). Unlike HIV-1 Vif, non-primate lentivirus BIV Vif assembles with CUL2 and the ElOB/C E3 component (Supplementary Figure S2E) and is not regulated by ACDBFGHEI.
CBFβ to trigger the degradation of bovine APOBEC3 (31). Since USP8 sequence is highly conserved between cow and human (Supplementary Figure S2F), human USP8 was also able to block BIV Vif-induced degradation of cow APOBEC3 in HEK293T cells (Supplementary Figures S2G, H). Importantly, we observed that diverse Vif expression could be enhanced by USP8 (Supplementary Figures S2A, C, G). Taken together, USP8 targets diverse Vif viral substrate receptors but not the E3 cellular components.

To identify whether the deubiquitinating enzymatic activity of USP8 is required for its antagonism of Vif function, a key residue Cysteine 786 of USP8 is mutated to abolish its enzymatic activity (21) (Figure 2E). We found that the active site mutant USP8 C786D lost the ability to inhibit Vif-mediated A3G degradation (Figure 2F, lane 4) when compared to wild-type USP8 (Figure 2F, lane 3). In the presence of USP8 C786D, Vif-mediated A3G degradation was as efficient as the no-USP8 control (Figure 2G, bar 4 vs. bar 2). USP8 is vital for the development and homeostasis of T cells and is cleaved in activated CD4+ T cells by caspases. The C-terminal fragment of USP8, but not N-terminal fragment, possesses the enzymatic activity (21). Somatic mutations in USP8 enhance its proteolytic cleavage and are associated with Cushing’s disease resulting from elevated deubiquitinate activity (22). We observed that the C-terminal fragment (C40) but not the N-terminal fragment (N90) of USP8 maintained the inhibitory activity against HIV-1 Vif (Figures 2H, I). Collectively, enzymatic activity of USP8 is critical for the inhibitory effect of Vif function.

USP8 Specifically Interacts With HIV-1 Vif and Reduces Vif-Triggered A3G Polyubiquitination

To explore the mechanism of USP8-mediated Vif inhibition, we employed co-immunoprecipitation (co-IP) assay to determine whether USP8 could interact with HIV-1 Vif. In the absence of Vif, USP8 was not detected in the co-IP sample (Figure 3A, lane 1), indicating the specificity of the assay system. In the presence of Vif, co-precipitation of USP8 with Vif was detected (Figure 3A, lane 3). Gads is a binding partner of USP8, which is required for USP8 in regulating the development and homeostasis of T cells (21). The interaction with HIV-1 Vif reduced the ability of USP8 binding with its functional cofactor Gads (Supplementary Figures S3A, B). These data establish a specific interaction between HIV-1 Vif and USP8. Vif forms a viral-specific E3 ubiquitin ligase complex with cellular proteins CUL5, ELOB/C, and CBFβ to trigger polyubiquitination of substrates (12). Vif interacts with USP8; we next assessed whether USP8 disrupts Vif–Cullin 5–E3 ubiquitin ligase complex assembly. Interestingly, USP8 did not interact with CUL5, ELOB, or CBFβ (Supplementary Figure S3C) in the absence of Vif. The ability of Vif to interact with CUL5, ELOB, and CBFβ (Figure 3B, lane 2; Figure 3C) was not affected by USP8 overexpression (Figure 3B, lane 3; Figure 3C). The interaction of Vif with the target protein A3G (Figure 3D, lane 3; Figure 3E) was also not affected by USP8 (Figure 3D, lane 4; Figure 3E). However, HIV-1 Vif-induced polyubiquitination of A3G (Figure 3F, lane 1) was significantly reduced in the presence of USP8 (Figure 3F, lane 2). In contrast, enzymatically defective USP8 C786D, which could not inhibit Vif-triggered A3G degradation, was disabled in suppressing HIV-1 Vif-induced polyubiquitination of A3G (Figure 3F, lane 3) when compared to the WT USP8 (Figure 3F, lane 2). Additionally, we confirmed that USP8 repressed Vif-mediated A3G polyubiquitination in vitro study (Supplementary Figures S3D–F). Ubiquitinated A3G was purified from HEK293T cells transfected with Ub-Flag, Vif-HA, and A3G-V5 using anti-V5 affinity purification. WT USP8 and functional dominant truncation C40, which purified from HEK293T cells and incubated with ubiquitinated A3G, decreased A3G polyubiquitination, while enzymatic mutation C786D was disabled (Supplementary Figure S3D). USP8 C40 purified from *Escherichia coli* reduced A3G polyubiquitination in a time-dependent fashion (Supplementary Figure S3E). Likewise, USP8 C40(C786D), an enzymatic mutant, lost the ability of A3G deubiquitination (Supplementary Figure S3F). Together, these results indicated that USP8 specifically interacts with Vif and deubiquitinates the ubiquitination of A3G mediated by Vif.

**HIV-1 Antagonizes USP8-Mediated Viral Suppression by Impairing USP8 Expression in CD4+ Cells**

Although USP8 exhibits strong inhibitory activity against Vif-mediated A3G degradation (Figure 1F), the anti-HIV-1 function of USP8 could be compromised during HIV-1 replication. Because USP8 expression was reduced in HIV-1-infected CD4+ T cells, which is based on mass spectrometry data published by several groups (17, 32, 33). In both H9 (Figures 4A, B and Supplementary Figure S4A) and Jurkat (Figures 4C, D and Supplementary Figure S4B) CD4+ T cells, HIV-1 infection resulted in depletion of USP8 proteins significantly. Moreover, the USP8 mRNA level was also reduced in HIV-1-infected T cells (Figures 4E, F), suggesting that down-modulation of USP8 expression by HIV-1 is at least partially the result of an alteration in USP8 mRNA transcription or RNA stability. The C-terminal fragment of USP8 contains the deubiquitinating enzymatic activity (22) and is a potent inhibitor of HIV-1 Vif function (Figure 2H). HIV-1 Vif-triggered A3G degradation was blocked slightly more efficiently by USP8 C40 than by full-length USP8 (Figure 4G), which was correlated with the inhibition of HIV-1 Vif-induced A3G polyubiquitination (Supplementary Figures S3D, S4C, D). To further validate USP8 C40 function during HIV-1 infection, USP8 C40 was transduced into CD4+ T cells (Figure 4H). Transduction with USP8 C40 in H9 cells that express endogenous APOBEC3 antiviral proteins (Figure 4I, lanes 3 and 4) significantly inhibited HIV-1 replication (Figure 4J). In contrast, USP8 C40 (Figure 4I, lanes 1 and 2) has no effect on HIV-1 replication (Figure 4K) when transduced in APOBEC3-negative Jurkat cells. These data demonstrate that modulation of USP8 function in CD4+ T cells can enhance the antiviral activity of APOBEC3 cytidine deaminases against HIV-1 even in the presence of Vif.
Specific Deubiquitinating Enzymes Suppress Different HIV/SIV Accessory Protein-Mediated Degradation of Host Restriction Factors

Ubiquitin modification is linked to many cellular processes. Diverse DUBs are involved in reversing protein ubiquitination and therefore modulate the outcome of this posttranslational modification. HIV-1 Vpr, HIV-1 Vpu, and HIV-2 Rod/SIVmac Vpx also form virus-specific E3 ubiquitin ligase complexes to mediate the polyubiquitination and degradation of various target proteins (Supplementary Figures S5A–C). However, in contrast to USP8-mediated Vif inhibition, USP8 had little effect on HIV-1 Vpr-mediated HLF degradation (Supplementary Figure S5G), HIV-1 Vpu-mediated BST-2 depletion (Supplementary Figure S5H), or HIV-2 Rod/SIVmac Vpx-mediated SAMHD1 degradation (Supplementary Figures S5I, J). Although USP8 had little effect on HIV-1 Vpr, HIV-1 Vpu, or HIV-2 Rod/SIVmac Vpx function, we identified other potent DUB inhibitors of HIV-1 Vpr, HIV-1 Vpu, and HIV-2 Rod/SIVmac Vpx (Figures 5A–D) after screening 32 USPs (Supplementary Figures S5D–F). USP7 inhibited HIV-1 Vpr-mediated HLF degradation (Figure 5A), USP33 inhibited HIV-1 Vpu-mediated BST-2 depletion (Figure 5B), and USP37 inhibited HIV-2 Rod/SIVmac Vpx-mediated SAMHD1 degradation (Figures 5C, D). Moreover, we investigated different USP functions in suitable cell lines as previously reported (16, 20, 34). Silencing USP7 in H9 T cells, HLF degradation was more efficient in shUSP7 cells in the presence of HIV-1 infection compared with its control cells (Figure 5E, lanes 2 and 4). As a result, silencing USP7 promoted HIV-1 infectivity (Supplementary Figure S5K).

FIGURE 3 | Ubiquitin-specific protease 8 (USP8) specifically interacts with HIV-1 virion infectivity factor (Vif) and reduces Vif-triggered apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3G) (A3G) polyubiquitination. (A) Co-precipitation of USP8 with Vif. HEK293T cells were transfected with USP8-HA, Vif-Myc alone, or both, as indicated. Cell lysates were prepared and immunoprecipitated using anti-Myc antibody conjugated to agarose beads 48 h after transfection. Cell lysates and precipitated samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and reacted with an anti-HA antibody to detect USP8-HA and an anti-Myc antibody to detect Vif-Myc. Tubulin was used as the loading control for the cell lysate. (B) USP8 does not affect Vif-CRL5 E3 ubiquitin ligase formation. HEK293T cells were transfected with Vif-Myc, USP8-HA, or both. Cell lysates were immunoprecipitated with anti-Myc antibody conjugated to agarose beads. Cell lysates and precipitated samples were analyzed by immunoblotting with the corresponding antibodies. Tubulin was used as the loading control for the cell lysate. (C) Relative binding ability of Vif with Cul5, CBFβ, and EloB in the presence or absence of USP8 was determined by ImageJ2X. Protein binding to Vif in lane 2 (B, upper blot) was set to 1.0. Data are means ± SD from n = 3 independent experiments. The statistical significance analyses were performed using two-sided unpaired t-tests (NS, not significant). (D) The association of Vif with A3G is also not affected by USP8. HEK293T cells were co-transfected with expression vectors as indicated. Cells were treated with 10 mM MG132 12 h before harvesting. Vif protein was immunoprecipitated from cell lysates with an anti-V5 antibody conjugated to agarose beads. Cell lysates and precipitated samples were analyzed by immunoblotting with the corresponding antibodies. Tubulin was used as the loading control for the cell lysate. (E) Quantification of co-precipitated Vif relative to A3G was determined by ImageJ2X. Data are means ± SD from n = 3 independent experiments. The statistical significance analyses were performed using two-sided unpaired t-tests (NS, not significant). (F) USP8 inhibits Vif-triggered polyubiquitination of A3G. HEK293T cells were transfected with the empty vector, Vif-HA, A3G-V5, Ub-Myc, or USP8-HA as indicated. Cells were treated with 10 mM MG132 for 12 h before harvesting. Cell lysates were prepared and immunoprecipitated using anti-V5 antibody conjugated to agarose beads 48 h after transfection. Cell lysates and precipitated samples were analyzed by immunoblotting with the corresponding antibodies. Immunoblotting results from panels (A, B, D, F) are representative of n = 3 independent experiments.
Meanwhile, similar result was demonstrated in shUSP33 HeLa cells that BST2 degradation was enhanced during HIV-1 infection (Figure 5F, lanes 2 and 4) and subsequently promoted HIV-1 infectivity (Supplementary Figure S5L). HIV-1 Pr55Gag was determined to demonstrate silencing USPs has no effect on virus replication (Figures 5E, F). SAMHD1 was degraded in THP-1 cells when infected with SIVmac virus. As expected, SIV-induced SAMHD1 degradation was more efficient in the absence of USP37 THP-1 cells (Figure 5G). Collectively, specific DUBs play important roles in virus–host relationships.

**DISCUSSION**

APOBEC3 cytidine deaminases are host restriction factors against HIV-1 and related retroviruses. HIV-1 Vif targets
APOBEC3 for polyubiquitination and subsequent degradation to ensure successful viral replication. A3G protein degradation by ubiquitination was mediated by Vif- and cullin-RING-independent pathway. It is reported that USP49 is a new antiviral factor. USP49 increased A3G protein expression by removing ubiquitin and enhanced its anti-HIV-1 activity (35).

Different from USP49, we discovered that USP8 is a potent and specific inhibitor of Vif. USP8 overexpression alone or knocking down has no effect on A3G protein stability (Figures 1D, F). Notably, USP8 bound Vif (Figure 3A) without disturbing Vif–Cullin-RING E3 complex assembly (Figure 3B) or Vif–A3G interaction (Figure 3D). USP8 blocked Vif-induced polyubiquitination and degradation of A3G (Figures 1D–H, 3F). Consequently, USP8 could attenuate the infectivity of HIV-1 in the presence of A3G and suppress HIV-1 replication in CD4+ T cells (Figure 4E). Meanwhile, both mRNA and protein expression levels of USP8 were significantly downregulated during HIV-1 infection in T cells (Figures 4A–D and Supplementary Figures S4A, B), which indicated that HIV-1 has evolved new antagonisms against USP8.
We also observed that diverse Vif expression could be enhanced by USP8 (Figures 2A, C, F, 3H and Supplementary Figures S2A, C, G). Importantly, USP8 has the ability to block the anti-A3G activity of Vif molecules from diverse HIV-1 subtypes as well as distant related lentiviral Vif molecules (Figure 1G and Supplementary Figures S2G, H). Taken together, USP8 targets diverse Vif viral substrate receptors, but not the E3 cellular components or A3G. USP8 antagonized the ability of HIV-1 Vif to suppress the antiviral function of A3G, resulting in an enhanced antiviral activity of A3G against Vif-containing HIV-1. Next, USP8 functions in primary CD4+ T cells and monocyte-derived macrophages (MDMs) from actual patients need to be validated in the future.

Deubiquitinating enzymatic activity of USP8 is required for its antagonism of Vif function. The active site mutant USP8 C786D lost the ability to inhibit Vif-mediated A3G degradation when compared to the WT USP8 (Figures 2F, G). During T-cell activation, USP8 is catalytically cleaved by proteolytic enzymes into N-terminal and C-terminal fragments (22). We observed that the C-terminal fragment (C40), but not the N-terminal fragment (N90), maintains deubiquitinase activity (22) and inhibitory activity against HIV-1 Vif (Figures 2F, 4G). In addition, we validated the inhibitory function of USP8 on Vif-mediated A3G polyubiquitination in vitro (Supplementary Figures S3D–F). Both WT USP8 and functional dominant truncation C40 decreased A3G polyubiquitination, while enzymatic mutation C786D was disabled (Supplementary Figures S3D–F).

USP8 is highly expressed in CD4+ T cells and myeloid cells, which are the preferred target cells of HIV-1. USP8 is a regulatory factor of the T-cell receptor complex and plays an important role in T-cell function. HIV-1 infection could interfere with T-cell function by disturbing the expression of USP8 (Figures 4A–F) or its interaction with Gads5 (Supplementary Figure S3A). We discovered that endogenous USP8 expression is significantly reduced in HIV-1-infected H9 and Jurkat cells (Supplementary Figures S4A, B). It is interesting to investigate whether any auxiliary proteins of HIV may play a role in it. Unfortunately, we did not observe any significant endogenous USP8 protein expression reduction rescued by Vif-, Vpu-, or Vpx-deficient HIV. Therefore, we speculate that the reduction of USP8 by HIV may not be through its single auxiliary protein. Multiple proteins are potentially involved, including the structural proteins, which needs study in the future.

Interestingly, DUB USP8 exhibits poor activity against HIV-1 Vpr, HIV-1 Vpu, and HIV-2 Rod/SIVmac Vpx. After screening 32 USP functions, we discovered that distinct DUBs inhibit Vpr-mediated HLTF degradation, Vpu-mediated BST-2 degradation (16), and HIV-2 Rod/SIVmacVpx-mediated SAMHD1 degradation (19, 20). Vpx relieves inhibition of HIV-1 infection of myeloid cells mediated by the SAMHD1 protein (19, 20). SAMHD1 restricts reverse transcription of HIV in myeloid cells and resting T cells through its dNTP triphosphohydrolase (dTNTase) activity to repress virus replication. Different from SAMHD1, A3G and BST2/Tetherin all impair HIV-1 progeny virus replication. A3G impairs HIV-1 replication by packaging into virions during virus production and inhibits viral reverse transcription in newly infected target cells (10). BST2/Tetherin inhibits HIV-1 release by directly tethering virions to cells (16, 36). Interestingly, whether Vpr could promote HIV-1 replication in T cells is still disputable, and evidence for its role in cycling T lymphocytes has been sparse. Lahouassa et al. (18) and Yan et al. (37), using a sensitive pairwise replication competition assay, demonstrated that Vpr antagonizes HLTF to promote HIV-1 replication more fitness when coinfected with HIV-1 Vpr defective virus. In our study, the degradation of A3G, BST2, and HLTF was enhanced by HIV/SIV accessory protein when specific USPs (USP8, USP7, and USP33) were knocked down. However, we did not observe any effect on the first-round virus replication, as determined by the intracellular Pr55Gag expression level (Figures 5E, F).

Importantly, USP7, USP8, or USP33 knocking down all promotes the HIV-1 progeny virus infectivity (Figures 1D, E and Supplementary Figures 5K, L). Therefore, specific USPs target different HIV/SIV accessory proteins to promote host restriction factors against HIVs/SIVs.

Ubiquitin modification of proteins and its reverse process, deubiquitination, regulate all aspects of cellular processes (1, 4, 5). Hijacking host ubiquitin pathways has been linked to the replication of diverse viruses (7). The role of DUBs in the interplay between viruses and the host has not been well characterized. In this study, we demonstrate that DUBs potentially inhibit viral evasion of host restriction and viral replication (Figure 6). Interestingly, distinct DUBs inhibit different viral proteins with different efficacies. Enhancing the antiviral activity of certain DUBs therefore represents an attractive strategy against HIVs/SIVs.

MATERIALS AND METHODS

Plasmid Construction

USP8, USP8 N90, and USP8 C40 were constructed by PCR amplification from USP8-HA/Flag (#79639; Addgene) and then inserted between the Sall and BamH1 sites of a C-terminal HA/Flag tag VR1012 vector. pET28a-USP8 C40 was constructed by PCR amplification from USP8-HA/Flag and then inserted into the pET28a-Plus vector with a 6xHis-tag at the N terminus. pET28a-USP8 C40 C786D was made from pET28a-USP8 C40 by site-directed mutagenesis. All the USP plasmids were purchased from Addgene. The infectious molecular clone pNL4-3 (WT HIV-1) (38), A3G-HA (13), A3G-V5 (13), HIV-1 NL4-3-Vif-HA (Vif-HA) (38), BIV-Vif-HA (39), A3Z2Z3-HA (39), HIV-2Vpx (40), SIVmac Vpx-HA (40, 41), SAMHD1-HA (41), A3F-V5 (28), A3C-HA (42), A3DE-HA (42), Vpu-Hyc (43) and BST-2-HA (43), A3H-HapII-HA (44), and renilla (45) were as previously described. Vifs from different HIV-1 subtypes have been previously described (26). Vpr-HA, HLTF-Flag, Vif (HxB2)-HA, Vif-Myc, and Vpx-Myc were obtained from the Institute of Virology and AIDS Research, First Hospital of Jilin University, and were as previously described (13, 38, 41).

Frontiers in Immunology | www.frontiersin.org 9 September 2021 | Volume 12 | Article 740713
Cells
HEK293T (CRL-11268; ATCC), HeLa (CRM-CCL-2; ATCC), and TZM-bl (PTA-5659; ATCC) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; HyClone) containing 10% heat-inactivated fetal bovine serum (FBS, 04-001-1; Biological Industries) and penicillin/streptomycin. H9 (HTB-176; ATCC), Jurkat (TIB-152; ATCC), and THP1 (TIB-202; ATCC) cells were purchased from the ATCC and maintained in Roswell Park Memorial Institute 1640 (RPMI-1640) medium (HyClone) with 10% FBS and penicillin/streptomycin. The peripheral blood mononuclear cells (PBMCs) were isolated through Ficoll gradient centrifugation, and the CD4+ T lymphocytes were then purified from the PBMCs with anti-CD4-specific antibody-coated microbeads (Miltenyi Biotec, Germany) according to the manufacturer’s instructions. CD4+ T lymphocytes were maintained in RPMI-1640 medium (HyClone) with 10% FBS and penicillin/streptomycin.

Transfection
DNA transfection was carried out using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. H9 and Jurkat cells were transfected using the Amaxa Cell Line Nucleofector Kit V (Lonza, Switzerland) with the program G-014 or X-001 according to the manufacturer’s instructions.

Reagents and Antibodies
The antibodies used in this study are as follows: β-tubulin monoclonal antibody (NMS-410P; Covance), Anti-CUL5 (sc-13014; Santa Cruz Biotechnology), anti-EloB (sc-1144; Santa Cruz Biotechnology), anti-CBFb (sc-166142; Santa Cruz Biotechnology), anti-Vif (GTX80393; GeneTex), anti-USP8 (A7031; ABclonal), anti-HA (901513; Biologend), anti-Myc (AHO0052; Invitrogen), anti-V5 (R960-25; Invitrogen), anti-SAMHD1 (TA502024; OriGene), anti-HLTF (14786-1-AP; Proteintech), anti-BST2 (13560-1-AP; Proteintech), anti-A3G (D221663; Sangon Biotech), anti-USP7 (20445-1-AP; Proteintech), anti-USP33 (20445-1-AP; Proteintech), anti-USP37 (18465-1-AP; Proteintech), anti-His (sc-8036; Santa Cruz Biotechnology). CAP24 mAb (1513) was purchased from the NIH AIDS Reagents Program. Secondary antibodies were alkaline phosphatase-conjugated anti-rabbit (115–055–045; Jackson ImmunoResearch) and anti-mouse (115–055–062; Jackson ImmunoResearch), HRP-conjugated anti-rabbit (NA934V; GE) and anti-mouse (sc-2005; Santa Cruz Biotechnology).

Immunoblot Analysis
For immunoblot analysis of cell-associated proteins, whole cell lysates were prepared as follows: Cells were collected in culture medium and centrifuged at 5,000 rpm for 5 min. Each supernatant was mixed with an appropriate volume of lysis buffer.
buffer (50 mM Tris–HCl, pH 7.8, with 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 4 mM EDTA) and corresponding 4× loading buffer (8% sodium dodecyl sulfate in 320 mM Tris–HCl, pH 6.8, with 40% glycerol and 0.002% bromphenol blue). Proteins were solubilized by heating for 30 min at 100°C, with occasional vortexing to shear cellular DNA. Cell lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). Proteins were transferred to NC membranes (10401396; GE Whatman) and reacted with appropriate antibodies as described in the text, e.g., 1:50 rabbit polyclonal anti-USP8 to detect USP8. Membranes were then incubated with the corresponding secondary antibody, and proteins were visualized using a hypersensitive ECL chemiluminescence detection kit (Proteintech) according to the manufacturer’s protocol; the assembled HIV-1 in the culture supernatants was evaluated by immunoblotting in Figure 11 and Supplementary Figure S11. HIV-1 in the culture supernatants was filtered through a 0.45-μm filter and mixed with corresponding 4× loading buffer (described above). Proteins were solubilized by heating for 15 min at 100°C with occasional vortexing, and the HIV-1 supernatants were subjected to immunoblotting.

**Co-Immunoprecipitation**

In Figure 3 and Supplementary Figures S3 and S4C, HEK293T cells were co-transfected with an expression vector as indicated. In Figures 3D, F and Supplementary Figure S4C, cells were treated with 10 mM MG132 (Sigma) 12 h prior to harvesting (12, 46, 47). Cells were harvested and lysed in lysis buffer (50 mM Tris, pH 7.5, with 150 mM NaCl, 1% NP-40, and complete protease inhibitor cocktail tablets) at 4°C for 1 h, then centrifuged at 10,000×g for 30 min. Precleared cell lysates were mixed with anti-V5 antibody (Figures 3D, F and Supplementary Figures S3A, S4C), anti-Myc antibody (Figures 3A, B) or anti-HA antibody (Supplementary Figure S3C)-conjugated protein G agarose beads and incubated at 4°C overnight. The second day, the beads were washed six times with washing buffer (20 mM Tris, pH 7.5, with 100 mM NaCl, 0.1 mM EDTA, and 0.05% Tween-20) and centrifuged at 800×g for 1 min each time. The beads were eluted with elution buffer (0.1 M glycine-HCl, pH 3.5). The eluted materials were then analyzed by SDS-PAGE and immunoblotting as previously described.

**RT-qPCR**

Total RNA was extracted with TRIzol reagent (15596-026; Invitrogen) according to the manufacturer’s instructions. RNA reverse transcription used EasyScript First-Strand cDNA Synthesis SuperMix (AE301; TransGen Biotech) according to the manufacturer’s instructions. The quantitative real-time polymerase chain reaction (qPCR) was carried out on an Mx3005P instrument (Agilent Technologies, Stratagene, USA) using Power SYBR® Green PCR Master Mix (2x) (4367659; ABI). The primers used in this study are as follows: glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-F: GCA AATTCCATGGCACCGT; GAPDH-R: TCGCCCACTTGTATTTTG; USP8-R: TCGAAGAAGTGGAAAAGCCT; USP8-RT-F: CTTTCTCTTTTGCTTCACAT. Data were normalized to the housekeeping GAPDH gene, and the relative abundance of the transcripts was calculated using Ct models.

**Chemical Synthesis of siRNA**

To generate knocking down USP8 cell lines, chemically synthesized short interfering RNA (siRNA) and a nonspecific control were purchased from RiboBio Co. Ltd. (Guangzhou, China). The siUSP8 sequences are as follows: sense, #1: GCA TAAAGGTGAAGTGCCGA; #2: GAAAAAGGAGAGGAT; #3: GCAAGAGGGGGCAAGAAA.

**Knockdown Cell Line Construction**

USP7/USP8/USP33/USP37-specific shRNAs with the following target sites were cloned in the lenti-retroviral vector pLKO.1-puro (Addgene). The shRNA sequences are as follows: USP7 shRNA: 5-CCGGGCTGGATTTGTGGTTACGTTACTCGAG TAAACGGAACAAATCCAGGTTTTTG-3; USP8 shRNA: 5-CCGGTAAGAGTCATGACAGTTGGCCCTAGGAGGC ACGTGGCACATACTCTTTTTC-3; USP33 shRNA 5-CCGGTCTCGACAGTGTTAAATTAACCTCGAGTTATTA AGCCACTGTCAGATTTTTTG-3; USP37 shRNA 5-CCGGATTGAGCAGATGCTCTCTAGCTCATCTTC TGCAATTCGCGTTTTTG-3. HEK293T cells were co-transfected with sh-USP7/USP8/USP33/USP37-pLKO.1 or pLKO.1 plus RRE, REV, and VSV-G expression vectors by using Lipofectamine 3000. At 48 h after transfection, supernatants containing packaged lentivirus were harvested and used to infect H9, Hela, or THP1 cells for 96 h as indicated. Puromycin (3 μg/ml for HEK293T, 5 μg/ml for Hela, and 1.5 μg/ml for THP1) was then added into the culture to screen for stable cell lines.

**HIV Infectivity and Detection**

HEK293T cells were transfected with pNL4-3 (WT HIV-1) plasmid; 48 h later, the supernatant was collected and filtered through a 0.45-μm filter. Then, cells were infected with pNL4-3 virus in the presence of diethylaminoethyl-dextran hydrochloride (DEAE; 20 μg/ml) for 30 h. The culture medium was changed 30 h after infection and replaced with fresh medium and harvested at the indicated time. HIV-1 infectivity was assessed using TZM-BL indicator cells. LTR-luciferase was activated when TZM-BL cells were infected by HIV-1. TZM-BL cells were seeded in 24-well format plates (2 × 104 cells/well); 24 h later, the cells were infected with the equivalent of 0.5 ng of HIV-1 p24 antigen in the presence of 20 μg/ml DEAE. Cells were collected and lysed after 48 h. LTR-luciferase activity was measured with the Dual-Luciferase Reporter Assay System (E1910; Promega) according to the manufacturer’s protocol.

**In Vitro Deubiquitination Assay**

Ubiquitinated A3G was isolated from HEK293T cells transfected with expression vectors of Ub-Flag, Vif-HA, and A3G-V5 and then purified from the cell extracts with anti-V5 antibody-conjugated protein G agarose beads. USP8 or its mutant was purified from HEK293T cells overexpressing USP8-HA or its mutant using anti-HA-Agarose antibody in IP buffer [1% (vol/vol) Triton X-100, 50 mM Tris–HCl pH 7.4, 50 mM EDTA,
150 mM NaCl, 10 mM NaF, 10% glycerol, and fresh protease inhibitor cocktail. For in vitro deubiquitination assay, ubiquitinated A3G protein was incubated with USP8 or its mutant in the deubiquitination buffer (20 mM Tris–HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 10 mM DTT, 5% glycerol) for 1 h at 37°C. The ubiquitinated A3G was analyzed by immunoblotting.

peET28a-USP8 C40 and peET28a-USP8 C40 C786D fusion protein were expressed in the strain of BL21(DE3) and purified by metal-affinity chromatography on chelation resin. For in vitro deubiquitination assay, ubiquitinated A3G protein was incubated with USP8 C40 or its mutant in the deubiquitination buffer (mentioned above) for the indicated time courses at 37°C. The ubiquitinated A3G was analyzed by immunoblotting.

Statistical Analysis
Data from the protein quantitative analysis and luciferase reporter assays are presented as means and standard derivations. Differences among groups were analyzed by ANOVA test (Stata Corp., College 251 Station, TX, USA) (NS, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS
XY and WG designed the experiments. WG, GL, YR, CZ, and JS performed the experiments. XY, SH, WG, and YR analyzed the data. HL, WWZ, BZ, WYZ, and YY provided technical support. XY, WG, and YR wrote the paper with help from all authors. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported in part by funding from the National Natural Science Foundation of China (81772169; 31970151; 31900457; 31900133, 82172239, 82102384, 81701988; 81772757), the Chinese Ministry of Science and Technology (2018ZX10731-101-001-014), and the National Natural Science Foundation of Zhejiang Province (LQ21C010001).

ACKNOWLEDGMENTS
We thank Deborah McClellan, PhD, for editing the English text of a draft of this manuscript and Zhaolong Li and Hong Wang for technical assistance.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.740713/full#supplementary-material
prior to harvesting. Cell lysates were prepared and immunoprecipitated overnight using anti-HA agarose beads. Cell lysates and precipitated samples were analyzed by immunoblotting with anti-HA, anti-Cul5, anti-CBF1, or anti-EloB antibody. Tubulin was used as the loading control for the cell lysate (n=3). (D) USP8 deubiquitinates A3G in vivo. Ubiquitinated A3G was purified from HEK293T cells transfected with Ub-Flag, Vif-HA and A3G-V5 using anti-FLAG affinity purification, HA-tagged USP8, USP8 C40 or USP8 C40C786D recombinant protein was purified by n=2–NTA beads. Ubiquitinated A3G-V5 was incubated with His-tagged USP8C40 for indicated times, followed by immunoblotting using antibodies against Ub-Flag and USP8-His. (E) Ubiquitinated A3G was purified from HEK293T cells transfected with Ub-Flag, Vif-HA and A3G-V5 using anti-V5 affinity purification. USP8 C40 and USP8 C40C786D recombinant protein was purified by n=2–NTA beads. Ubiquitinated A3G-V5 was incubated with His-tagged USP8C40 or USP8 C40C786D for 1h, followed by immunoblotting using antibodies against Ub-Flag and USP8-His. Results from (A–F) are representative of n=3 independent experiments.

Supplementary Figure 4 | HIV-1 antagonizes USP8 suppression in CD4+ cells, and USP8 C40 inhibits HIV-1 Vif-induced A3G polyubiquitination. (A, B) HIV-1 suppresses USP8 expression at the protein level. H9 (A) and Jurkat (D) cells were infected with WT HIV or not for 48 h and 72h. Endogenous USP8 was analyzed by immunoblotting. Virus infection was determined by the presence of Pr65Gag. Tubulin was used as a loading control. USP8 expression was measured by ImageJ2X (mock infection was set to 100%). (C) The C terminus of USP8 is important for the inhibition of Vif-induced A3G degradation. HEK293T cells were transfected with Vif-HA, A3G-V5, and Ub-Myc in the presence of WT USP8, a truncation (N609 or C40), or control vector. Cells were treated with 10 mM MG132 for 12 h prior to harvesting. Cell lysates were prepared and immunoprecipitated overnight using anti-V5 antibody conjugated to agarose beads. Cell lysates and precipitated samples were analyzed by immunoblotting with the corresponding antibodies. (D) A3G ubiquitination was measured by ImageJ2X; A3G mock was set to 100%. Means and standard deviations are from three independent experiments. The statistical significance analyses were performed using two-tailed unpaired t-tests (NS, not significant; ***p<0.001).

Supplementary Figure 5 | (A) Model showing how HIV-1 Vpr assembles E3 ubiquitin ligase complexes to target HLA restriction protein polyubiquitination and degradation. (B) Model showing how HIV-1 Vpu assembles E3 ubiquitin ligase complexes to target SAMHD1 protein polyubiquitination and degradation. (C) Model showing how HIV-2/SIV Vpx assembles E3 ubiquitin ligase complexes to target SAMHD1 protein polyubiquitination and degradation. (D) Screening 32 USPs function on inhibiting Vpr-mediated HLA restriction. HEK293T cells were transfected with WT-HA and Vpr-HA or its empty vector in the presence of 32 USPs. Cells were harvested 48 h after transfection; protein expression in the cell lysates was analyzed by immunoblotting. Quantification of HLA expression was analyzed by ImageJ2X. HLA expression alone was normalized to 100%. (E) Screening 32 USPs function on inhibiting Vpu-mediated BST2 degradation. Quantification of BST2 expression was analyzed by ImageJ2X. BST2 expression alone was normalized to 100%. (F) Screening 32 USPs function on inhibiting Vpx-mediated SAMHD1 degradation. Quantification of SAMHD1 expression was analyzed by ImageJ2X. SAMHD1 expression alone was normalized to 100%. USP8 does not inhibit HIV-1 Vpu-induced BST-2 degradation. (I, J) USP8 does not inhibit HIV-2/SIV Vpx-induced SAMHD1 degradation. (K, L) Virus infectivity was assessed using TZM-BL indicator cells. shCON virus infectivity was set as 100%. Results from D-J are representative of n=3 independent experiments. Means and standard deviations are from three independent experiments. The statistical significance analyses were performed using two-tailed unpaired t-tests (NS, not significant; ***p<0.001; **p<0.01; *p<0.05).

REFERENCES
1. Swatek KN, Komander D. Ubiquitin Modifications. Cell Res (2016) 26:399–422. doi: 10.1038/cr.2016.39
2. Sahote DD, Sixma TK. Layers of DUB Regulation. Trends Biochem Sci (2015) 40:456–67. doi: 10.1016/j.tib.2015.05.002
3. Clague M, Barsukov I, Coulson J, Liu H, Rigden D, Urbe S. Deubiquitylases From Genes to Organisms. Physiol Rev (2013) 93:1289–315. doi: 10.1152/physrev.00002.2013
4. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the Human Deubiquitinating Enzyme Interaction Landscape. Cell (2009) 138:389–403. doi: 10.1016/j.cell.2009.04.042
5. Berndsen CE, Wolberger C. New Insights Into Ubiquitin E3 Ligase Mechanism. Nat Struct Mol Biol (2014) 21:301–7. doi: 10.1038/nsmb.2790
6. Reyes-Turcu FE, Wilkinson KD. Polyubiquitin Binding and Disassembly by Deubiquitinating Enzymes. Chem Rev (2009) 109:1495–508. doi: 10.1021/ cr800470j
7. Calistri A, Munegato D, Carli I, Parolin C, Palu G. The Ubiquitin-Conjugating System: Multiple Roles in Viral Replication and Infection. Cells (2014) 3:336–417. doi: 10.3390/cells3020386
8. Osei Kuffour E, Schott K, Jagua Vasudevan AA, Holler J, Schulz WA, Lang PA, et al. USP18 (UBP43) Abrogates P21-Mediated Inhibition of HIV-1. J Virol (2018) 92(10). doi: 10.1128/JVI.00592-18
9. Malim MH, Emerman M. HIV-1 Accessory Proteins–Ensuring Viral Survival in a Hostile Environment. Cell Host Microbe (2008) 3:388–98. doi: 10.1016/j.chom.2008.04.008
10. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA Deamination Mediates Innate Immunity to Retroviral Infection. Cell (2003) 113(6):803–9. doi: 10.1016/s0092-8674(03)00429-9
11. Weinrich S, Gallaway NL, Greene WC. HIV-1 Vif Versus the APOBEC3 Cytidine DNA Methyltransferase. Nat Immunol (2010) 31:383–97. doi: 10.1016/j.nima.2010.06.001
12. Zhang W, Du J, Evans SL, Yu Y, Yu X, F. T-Cell Differentiation Factor CRB-Reta Regulates HIV-1 Vif-Mediated Evasion of Host Restriction. Nature (2011) 481:376–9. doi: 10.1038/nature10718
13. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cull5-SCF Complex. Science (2003) 302:1056–60. doi: 10.1126/science.1089591
14. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H, et al. Structural Basis for Hijacking CRB-β and CUL3 E3 Ligase Complex by HIV-1 Vif. Nature (2014) 510:229–33. doi: 10.1038/nature12884
15. Simon V, Bloch N, Landsdorp VR. Intrinsic Host Restriction to HIV-1 and Mechanisms of Viral Escape. Nat Immunol (2015) 16:546–53. doi: 10.1038/ nli.2015
16. Neil SJ, Zang T, Bieniasz PD. Tetherin Inhibits Retrovirus Release and Is Antagonized by HIV-1 Vpu. Nature (2008) 451:425–30. doi: 10.1038/ nature06553
17. Liu Y, Fu Y, Wang Q, Li M, Zhou Z, Dabbagh D, et al. Proteomic Profiling of HIV-1 Infection of Human CD4+ T Cells Identifies PSG1-1 as an HIV Restriction Factor. Nat Microbiol (2019) 4:813–25. doi: 10.1038/s41564-019- 0372-2
18. Lahouassa H, Blondot ML, Chauveau L, Chougui G, Morel M, Leduc M, et al. HIV-1 Vpr Depgrades the HLA DNA Translocase in T Cells and Macrophages. Proc Natl Acad Sci USA (2016) 113:5331–6. doi: 10.1073/ pnas.1600481113
19. Hrecka K, Hao C, Gierszewski M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx Relieves Inhibition of HIV-1 Infection of Macrophages Mediated by the SAMHD1 Protein. Nature (2011) 474:658–61. doi: 10.1038/nature10195
20. Laguette N, Sobbian B, Casartelli N, Ringoard M, Chable-Bessa C, Segéral E, et al. SAMHD1 Is the Dendritic- and Myeloid-Cell-Specific HIV-1 Restriction Factor Counteracted by Vpx. Nature (2011) 474:654–7. doi: 10.1038/ nature10117
21. Dunfer A, Kisser A, Niendorf S, Basters A, Reissig S, Schönle A, et al. The Ubiquitin-Specific Protease USP8 Is Critical for the Development and Homeostasis of T Cells. Nat Immunol (2015) 16:950–60. doi: 10.1038/ni.3230
22. Reincke M, Sbiera S, Hayakawa A, Theodoroupolou M, Osswald A, Beuschlein F, et al. Mutations in the Deubiquitinase Gene USP8 Cause High-Tone Deafness. J Virol (2015) 89:4731–8. doi: 10.1128/jvi.02366-14
23. Jäger S, Kim DY, Hulquist JF, Shindo K, LaRue RS, Kwon E, et al. Vif Hijacks CBF-Beta to Destabilize APOBEC3G and Promote HIV-1 Infection. Nature (2011) 481:371–5. doi: 10.1038/nature10693
24. Hache G, Shindo K, Albin JS, Harris RS. Evolution of HIV-1 Isolates That Use a Novel Vif-Independent Mechanism to Resist Restriction by Human APOBEC3G. Curr Biol (2008) 18:819–24. doi: 10.1016/j.cub.2008.04.073
25. Fujita M, Akari H, Sakurai A, Yoshida A, Chiba T. Expression of HIV-1 Accessory Protein Vif Is Controlled Uniquely to be Low and Optimal by Proteasome Degradation. Microbes Infect (2004) 6:791–8. doi: 10.1016/j.micinf.2004.04.011
26. Zhao K, Du J, Rui Y, Zheng W, Kang J, Hou J, et al. Evolutionarily Conserved Pressure for the Existence of Distinct G2/M Cell Cycle Arrest and AHI Inactivation Functions in HIV-1 Vif. Cell Cycle (2015) 14:838–47. doi: 10.1080/15384101.2014.1000212
27. Binka M, Ooms M, Steward M, Simon V. The Activity Spectrum of Vif From Multiple HIV-1 Subtypes Against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2012) 86:49–59. doi: 10.1128/jvi.00684-11
28. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF. Regulation of Apobec3F and Human Immunodeficiency Virus Type 1 Vif by Vif-Cul5-EloB/C E3 Ubiquitin Ligase. J Virol (2005) 79:9579–87. doi: 10.1128/JVI.79.15.9579-9587.2005
29. Zhao K, Du J, Zhao X, Xiong Y, Yu XF. A Single Amino Acid Difference in Human APOBEC3VIF Variants Determines HIV-1 Vif Sensitivity. J Virol (2010) 84:1902–11. doi: 10.1128/JVI.01509-09
30. Larue RS, Lengyl J, Jonsson SR, Andresottt V, Harris RS. Lentiviral Vif Deprades the APOBEC3Z3/APOBEC3H Protein of its Mammanian Host and Is Capable of Cross-Species Activity. J Virol (2010) 84:8193–201. doi: 10.1128/JVI.00685-10
31. Zhang J, Wu J, Wang W, Wu H, Yu B, Wang J, et al. Role of cullin-elonginB-elonginC E3 Complex in Bovine Immunodeficiency Virus and Maedi-Visna Virus Vif-Mediated Degradation of Host AS22-Z3 Proteins. Retrovirology (2014) 11:77. doi: 10.1186/s12977-014-0077-9
32. Greenwood EL, Matheson NJ, Wals K, van den Boomen DJ, Antrobus R, Williamson JC, et al. Temporal Proteomic Analysis of HIV Infection Reveals Remodelling of the Host Phosphoproteome by Lentiviral Vif Variants. Elife (2016) 5. doi: 10.7554/elife.18296
33. Matheson NJ, Sumner J, Wals K, Rapiteam R, Weekes MP, Vigan R, et al. Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. Cell Host Microbe (2015) 18:409–23. doi: 10.1016/chom.2015.09.003
34. Decorsiere A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, et al. Hepatitis B Virus X Protein Identifies the Smc5/6 Complex as a Host Restriction Factor. Nature (2016) 531:386–9. doi: 10.1038/nature17170
35. Pan T, Song Z, Wu L, Liu G, Ma X, Peng Z, et al. USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication. Elife (2019) 8. doi: 10.7554/elife.48318
36. Perez-Caballero D, Zang T, Ebrahimzadeh A, McNutt MW, Gregory DA, Johnson MC, et al. Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. Cell (2009) 139:499–511. doi: 10.1016/j.cell.2009.08.039
37. Yan J, Shun MC, Zhang Y, Hao C, Skowronska J. HIV-1 Vpr Counteracts HLTF-Mediated Restriction of HIV-1 Infection in T Cells. Proc Natl Acad Sci USA (2019) 116(19):9568–77. doi: 10.1073/pnas.181401116
38. Wang H, Liu B, Liu X, Li Z, Yu XF, Zhang W. Identification of HIV-1 Vif Regions Required for CBF-Beta Interaction and APOBEC3 Suppression. PloS One (2014) 9:e81258–40. doi: 10.1371/journal.pone.0095738
39. Zhao K, Wang H, Li Z, Liu X, Liu G, Harris RS, et al. Cellular Requirements for Bovine Immunodeficiency Virus Vif-Mediated Inactivation of Bovine APOBEC3 Proteins. J Virol (2014) 88:12528–40. doi: 10.1128/JVI.02072-14
40. Wei W, Guo H, Liu X, Zhang H, Qian L, Luo K. A First-in-Class NAE Inhibitor, MLN4924, Blocks Lentiviral Infection in Myeloid Cells by Disrupting Neddylation-Dependent Vpx-Mediated SAMHD1 Degradation. J Virol (2014) 88:745–51. doi: 10.1128/JVI.02568-13
41. Wei W, Guo H, Gao Q, Markham R, Yu XF. Variation of Two Primate Lineage-Specific Residues in Human SAMHD1 Confers Resistance to N-Terminus-Targeted SIV Vpx Proteins. J Virol (2014) 88:583–91. doi: 10.1128/JVI.02866-13
42. Zhang W, Chen G, Niewiadomska AM, Xue R, Yu XF. Distinct Determinants in HIV-1 Vif and Human APOBEC Proteins Are Required for the Suppression of Diverse Host Anti-Viral Proteins. PloS One (2008) 3:e3963. doi: 10.1371/journal.pone.0003963
43. Lu M, Zhang B, Shi Y, Han Z, Zhang Y, Zhou Y, et al. Identification of BST-2/Tetherin-Induced Hepatitis B Virus Restriction and Hepatocyte-Specific BST-2 Inactivation. Sci Rep (2015) 5:11736. doi: 10.1038/srep11736
44. Zhao A, Du J, Zhou X, Xiong Y, Yu XF. Reduced APOBEC3H Variant Anti-Viral Activities Are Associated With Altered DNA Binding Activities. PloS One (2014) 9:e95738. doi: 10.1371/journal.pone.0095738
45. Su J, Rui Y, Lou M, Yin L, Xiong H, Zhou Z, et al. HIV-2/SIV Vpx Targets a Novel Functional Domain of STING to Selectively Inhibit cGAS-STING-Mediated NF-kappaB Signalling. Nat Microbiol (2019) 4:2552–64. doi: 10.1038/s41564-019-0585-4
46. Wu HT, Kuo YC, Huang JJ, Huang CH, Chen WY, Chou TY, et al. K63-Polyubiquitinated HAUSP Deubiquitinates HIV-1 Vif and Inhibits HIV-1 Infection. J Virol (2015) 89:9573–81. doi: 10.1128/JVI.02568-13
47. Liu X, Yao Y, Ding H, Han C, Chen Y, Zhang Y, et al. USP21 Deubiquitylates Nanog to Regulate Protein Stability and Stem Cell Pluripotency. Signal Transduct Target Ther (2016) 1:16024. doi: 10.1038/sigtrans.2016.24

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by it, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Gao, Rui, Li, Zhai, Su, Liu, Zheng, Zheng, Yang, Hua and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.